Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches
- PMID: 24657660
- DOI: 10.1016/j.canlet.2014.03.013
Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches
Abstract
Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer chemotherapies. The mechanisms of MDR and the approaches to test MDR have been discovered, yet not fully understood. This review covers the in vivo and in vitro approaches for the detection of MDR in the laboratory and the mechanisms of MDR in cancers. This study also envisages the future developments toward the clinical and therapeutic applications of MDR in cancer treatment. Future therapeutics for cancer treatment will likely combine the existing therapies with drugs originated from MDR mechanisms such as anti-cancer stem cell drugs, anti-miRNA drugs or anti-epigenetic drugs. The challenges for the clinical detection of MDR will be to find new biomarkers and to determine new evaluation systems before the drug resistance emerges.
Keywords: Biomarker; Cancer; Chemotherapy; Lab approach; Mechanism; Multi-drug resistance (MDR).
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
The Roles of microRNAs in Multidrug-Resistance Mechanisms in Gastric Cancer.Curr Mol Med. 2020;20(9):667-674. doi: 10.2174/1566524020666200226124336. Curr Mol Med. 2020. PMID: 32209033 Review.
-
miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.Cancer Chemother Pharmacol. 2012 Mar;69(3):723-31. doi: 10.1007/s00280-011-1752-3. Epub 2011 Oct 13. Cancer Chemother Pharmacol. 2012. PMID: 21993663
-
Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy?Mol Pharm. 2014 Aug 4;11(8):2527-38. doi: 10.1021/mp500066v. Epub 2014 Jun 20. Mol Pharm. 2014. PMID: 24921216 Review.
-
Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review.Taiwan J Obstet Gynecol. 2009 Sep;48(3):239-44. doi: 10.1016/S1028-4559(09)60296-5. Taiwan J Obstet Gynecol. 2009. PMID: 19797012 Review.
-
Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.Methods Find Exp Clin Pharmacol. 2007 Nov;29(9):607-17. doi: 10.1358/mf.2007.29.9.1139054. Methods Find Exp Clin Pharmacol. 2007. PMID: 18193112 Review.
Cited by
-
Heterocycles in Breast Cancer Treatment: The Use of Pyrazole Derivatives.Curr Med Chem. 2023;30(10):1145-1174. doi: 10.2174/0929867329666220829091830. Curr Med Chem. 2023. PMID: 36043746 Free PMC article. Review.
-
Biased random walk model for the prioritization of drug resistance associated proteins.Sci Rep. 2015 Jun 3;5:10857. doi: 10.1038/srep10857. Sci Rep. 2015. PMID: 26039373 Free PMC article.
-
Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives.J Nanobiotechnology. 2021 Apr 17;19(1):110. doi: 10.1186/s12951-021-00861-0. J Nanobiotechnology. 2021. PMID: 33865432 Free PMC article. Review.
-
Impairment of cell adhesion and migration by inhibition of protein disulphide isomerases in three breast cancer cell lines.Biosci Rep. 2020 Oct 30;40(10):BSR20193271. doi: 10.1042/BSR20193271. Biosci Rep. 2020. PMID: 33095243 Free PMC article.
-
Dual Sensitization Anti-Resistant Nanoparticles for Treating Refractory Breast Cancers via Apoptosis-Inducing.Drug Des Devel Ther. 2023 Feb 10;17:403-418. doi: 10.2147/DDDT.S387788. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 36798807 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous